Asterias Biotherapeutics Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)
Go back to Asterias Biotherapeutics Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)| Hastings Entertainment, Inc. (NYSE: AST) | Delayed: 0.95 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.95 | 52 Week High | $5.75 | |||
| Open | $19.21 | 52 Week Low | $2.30 | |||
| Day High | $0.95 | P/E | 1.02 | |||
| Day Low | $0.95 | EPS | $0.93 | |||
| Volume | 1 | |||||
